Novo Nordisk A/S (Copenhagen: NOVO B)
2880 Bagsværd, Denmark (Map) Phone: +45-4444-8888
Fax: +45-4449-0555
Primary US Office:
Subscribers Only http://www.novonordisk.com
Overview
Novo Nordisk gives diabetics the tools to stick it to their disease. One of the world's leading producers of insulin, Novo Nordisk also makes insulin analogues, injection devices, and diabetes education materials. Its products include analogues Levemir and NovoLog (which mimic natural insulin regulation more closely than human insulin) and the FlexPen, a pre-filled insulin injection tool. In addition to its diabetes portfolio, the firm has products in the areas of hemostasis management (blood clotting), human growth hormone, and hormone replacement therapy. The not-for-profit Novo Nordisk Foundation, through its Novo A/S subsidiary, controls more than two-thirds of the voting power in Novo Nordisk.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for Novo Nordisk A/S (Copenhagen: NOVO B)
| Company Type | Public (Copenhagen: NOVO B; NYSE: NVO [ADR]) |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | £4,136.6 |
| 1-Year Sales Growth | 20.5% |
| 2007 Net Income (mil.) | £842.7 |
| 1-Year Net Income Growth | 50.7% |
| 2007 Employees | 26,000 |
| 1-Year Employee Growth | 13.0% |
Key People from Hoover's UK
Key people and executives for Novo Nordisk A/S (Copenhagen: NOVO B)
| Chairman | Sten Scheibye (Subscribers see complete biographies -- view sample)
Connect to this executive |
|---|---|
| President and CEO | Lars Rebien Sørensen Connect to this executive |
| EVP and CFO | Jesper Brandgaard Connect to this executive |
Top Competitors from Hoover's UK
Top competitors of Novo Nordisk A/S (Copenhagen: NOVO B)
There are 17 competitors for Novo Nordisk; see more.Industry Information from Hoover's UK
First Research Industry Profiles Extensive Industry Intelligence
Hoover's Industries
More Industry InformationRankings from Hoover's UK
See how Novo Nordisk A/S (Copenhagen: NOVO B) ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones
- #229 in FT Global 500
